Skip to main content

Rapacuronium Pregnancy and Breastfeeding Warnings

Rapacuronium is also known as: Raplon

Rapacuronium Pregnancy Warnings

Rapacuronium has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of fetotoxicity and increased resorption. There are no controlled data in human pregnancy. It has been reported that following a single maternal dose, there was a passage of low levels of rapacuronium across the placenta and slow elimination. Rapacuronium is only recommended for use during pregnancy if the potential benefit to the patient outweighs the potential risk to the fetus. This warning does not apply to the use of rapacuronium during Cesarean section. However, monitoring of the infant is recommended after delivery.

See references

Rapacuronium Breastfeeding Warnings

There are no data on the excretion of rapacuronium into human milk. Because many drugs are excreted into human milk, caution is recommended if rapacuronium is to be used in a nursing mother.

See references

References for pregnancy information

  1. Product Information. Raplon (rapacuronium). Organon. 2001.

References for breastfeeding information

  1. Product Information. Raplon (rapacuronium). Organon. 2001.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.